Literature DB >> 21708485

High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv.

Robert C Reynolds1, Subramaniam Ananthan, Ellen Faaleolea, Judith V Hobrath, Cecil D Kwong, Clinton Maddox, Lynn Rasmussen, Melinda I Sosa, Elizabeth Thammasuvimol, E Lucile White, Wei Zhang, John A Secrist.   

Abstract

Kinase targets are being pursued in a variety of diseases beyond cancer, including immune and metabolic as well as viral, parasitic, fungal and bacterial. In particular, there is a relatively recent interest in kinase and ATP-binding targets in Mycobacterium tuberculosis in order to identify inhibitors and potential drugs for essential proteins that are not targeted by current drug regimens. Herein, we report the high throughput screening results for a targeted library of approximately 26,000 compounds that was designed based on current kinase inhibitor scaffolds and known kinase binding sites. The phenotypic data presented herein may form the basis for selecting scaffolds/compounds for further enzymatic screens against specific kinase or other ATP-binding targets in Mycobacterium tuberculosis based on the apparent activity against the whole bacteria in vitro.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21708485      PMCID: PMC3183257          DOI: 10.1016/j.tube.2011.05.005

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  55 in total

1.  ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds.

Authors:  Gemma Triola; Stefan Wetzel; Bernhard Ellinger; Marcus A Koch; Katja Hübel; Daniel Rauh; Herbert Waldmann
Journal:  Bioorg Med Chem       Date:  2008-02-16       Impact factor: 3.641

Review 2.  Targeting cancer with small molecule kinase inhibitors.

Authors:  Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

3.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.

Authors:  Subramaniam Ananthan; Ellen R Faaleolea; Robert C Goldman; Judith V Hobrath; Cecil D Kwong; Barbara E Laughon; Joseph A Maddry; Alka Mehta; Lynn Rasmussen; Robert C Reynolds; John A Secrist; Nice Shindo; Dustin N Showe; Melinda I Sosa; William J Suling; E Lucile White
Journal:  Tuberculosis (Edinb)       Date:  2009-09-15       Impact factor: 3.131

4.  Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord.

Authors:  Philip Duffy; Andre Schmandke; Antonio Schmandke; Jonathan Sigworth; Shuh Narumiya; William B J Cafferty; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

5.  Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.

Authors:  Yan Yin; Li Lin; Claudia Ruiz; Michael D Cameron; Jennifer Pocas; Wayne Grant; Thomas Schröter; Weimin Chen; Derek Duckett; Stephan Schürer; Philip Lograsso; Yangbo Feng
Journal:  Bioorg Med Chem Lett       Date:  2009-10-03       Impact factor: 2.823

6.  Antituberculosis activity of the molecular libraries screening center network library.

Authors:  Joseph A Maddry; Subramaniam Ananthan; Robert C Goldman; Judith V Hobrath; Cecil D Kwong; Clinton Maddox; Lynn Rasmussen; Robert C Reynolds; John A Secrist; Melinda I Sosa; E Lucile White; Wei Zhang
Journal:  Tuberculosis (Edinb)       Date:  2009-09-26       Impact factor: 3.131

7.  Discovery of 2-(5-nitrothiazol-2-ylthio)benzo[d]thiazoles as novel c-Jun N-terminal kinase inhibitors.

Authors:  Surya K De; Li-Hsing Chen; John L Stebbins; Thomas Machleidt; Megan Riel-Mehan; Russell Dahl; Vida Chen; Hongbin Yuan; Elisa Barile; Aras Emdadi; Ria Murphy; Maurizio Pellecchia
Journal:  Bioorg Med Chem       Date:  2009-02-26       Impact factor: 3.641

8.  Discovery and validation of new antitubercular compounds as potential drug leads and probes.

Authors:  Robert C Goldman; Barbara E Laughon
Journal:  Tuberculosis (Edinb)       Date:  2009-08-28       Impact factor: 3.131

9.  Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

Authors:  Qi Chao; Kelly G Sprankle; Robert M Grotzfeld; Andiliy G Lai; Todd A Carter; Anne Marie Velasco; Ruwanthi N Gunawardane; Merryl D Cramer; Michael F Gardner; Joyce James; Patrick P Zarrinkar; Hitesh K Patel; Shripad S Bhagwat
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

10.  Uncovering new signaling proteins and potential drug targets through the interactome analysis of Mycobacterium tuberculosis.

Authors:  Tao Cui; Lei Zhang; Xizhou Wang; Zheng-Guo He
Journal:  BMC Genomics       Date:  2009-03-19       Impact factor: 3.969

View more
  42 in total

1.  Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.

Authors:  Sean Ekins; Nadia K Litterman; Christopher A Lipinski; Barry A Bunin
Journal:  Pharm Res       Date:  2015-08-27       Impact factor: 4.200

2.  Small molecule inhibitors of trans-translation have broad-spectrum antibiotic activity.

Authors:  Nitya S Ramadoss; John N Alumasa; Lin Cheng; Yu Wang; Sharon Li; Benjamin S Chambers; Hoon Chang; Arnab K Chatterjee; Achim Brinker; Ingo H Engels; Kenneth C Keiler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-03       Impact factor: 11.205

3.  Computational models for neglected diseases: gaps and opportunities.

Authors:  Elizabeth L Ponder; Joel S Freundlich; Malabika Sarker; Sean Ekins
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

4.  6-Oxo and 6-thio purine analogs as antimycobacterial agents.

Authors:  Ashish K Pathak; Vibha Pathak; Lainne E Seitz; William J Suling; Robert C Reynolds
Journal:  Bioorg Med Chem       Date:  2013-02-04       Impact factor: 3.641

Review 5.  Adapting high-throughput screening methods and assays for biocontainment laboratories.

Authors:  Lynn Rasmussen; Bersabeh Tigabu; E Lucile White; Robert Bostwick; Nichole Tower; Alexander Bukreyev; Barry Rockx; James W LeDuc; James W Noah
Journal:  Assay Drug Dev Technol       Date:  2015 Jan-Feb       Impact factor: 1.738

6.  Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis.

Authors:  Sean Ekins; Allen C Casey; David Roberts; Tanya Parish; Barry A Bunin
Journal:  Tuberculosis (Edinb)       Date:  2013-12-19       Impact factor: 3.131

Review 7.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

Review 8.  Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

Authors:  Sean Ekins; Anna Coulon Spektor; Alex M Clark; Krishna Dole; Barry A Bunin
Journal:  Drug Discov Today       Date:  2016-11-22       Impact factor: 7.851

9.  Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery.

Authors:  Sean Ekins; Robert C Reynolds; Hiyun Kim; Mi-Sun Koo; Marilyn Ekonomidis; Meliza Talaue; Steve D Paget; Lisa K Woolhiser; Anne J Lenaerts; Barry A Bunin; Nancy Connell; Joel S Freundlich
Journal:  Chem Biol       Date:  2013-03-21

10.  Are bigger data sets better for machine learning? Fusing single-point and dual-event dose response data for Mycobacterium tuberculosis.

Authors:  Sean Ekins; Joel S Freundlich; Robert C Reynolds
Journal:  J Chem Inf Model       Date:  2014-07-17       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.